DAV VAGINAL CAPSULES contains alpha-lipoic acid (ALA), an endogenous fatty acid with antioxidant properties able to counteract free radicals released at the extracellular level during inflammatory processes. These processes are responsible for alterations of the extracellular matrix and cause tissue changes. DAV vaginal capsules exerts a normalizing effect, helping to counteract alterations in cervical and vaginal tissues.
The physiological course of pregnancy can be threatened by the onset of uterine contractions associated with dilatations of the uterine neck. Often these changes are a consequence of inflammatory processes; in such cases tocolytic therapies could be useful to counteract morphological alterations concerning the cervix. In addition, it is often oxygen free radicals that cause changes that could change the course of a pregnancy. ROS are involved in the pathogenesis of spontaneous abortion because:
1. They cause lipid peroxidation of embryo cells;
2. Reduce HIF-1α concentrations (hypoxia-inducible factor 1-alpha) and consequently the ability to adapt to hypoxic conditions;
3. As a consequence of the previous point, the trophoblast enters a process of ischemia-reperfusion which damages the embryo, further increasing the levels of oxidative stress.
Some studies have shown that supplementation with ALA helps to restore physiological conditions when there are suspected cases of miscarriage. This is probably due to the ability of ALA to modulate the action of cytokines, growth factors and other molecules.
Each 400 mg vaginal capsule contains: alpha-lipoic acid, microcrystalline cellulose, magnesium stearate, silicon dioxide, hydroxypropyl methylcellulose, titanium dioxide.
It is a medical device CE 0373. Carefully read the warnings or instructions for use. Authorization of the Ministry of Health 11/28/2017.
